MyMD Pharmaceuticals Enrolls First Client in Stage 2 Professional Test of MYMD-1 as a Therapy for Delaying Aging as well as Extending Healthy And Balanced Life Expectancy

MyMD Pharmaceuticals, Inc. MYMD Stock (” MyMD” or “the Company”), a scientific stage pharmaceutical company committed to extending healthy lifespan, today announced that the initial person has actually been enrolled in the Company’s Stage 2 medical test of lead prospect MYMD-1, an oral immune regulatory authority medication, as a treatment for postponing aging and expanding healthy and balanced lifespan.

The key endpoint for the Phase 2 double-blind, placebo-controlled professional trial is to attain a decrease in the flowing degrees of (TNF-α), tumor death aspect receptor I (TNFRI) and IL-6. TNF-α and also IL-6 are the proteins in the body that trigger swelling and help trigger the process of aging. The secondary measures of the test will certainly be the safety and security, tolerability, and pharmacokinetics in this population of people.

” In a Stage 1 clinical trial of MYMD-1, we showed the medication’s statistically significant effectiveness in minimizing levels of TNF-α, a key player in triggering pathological aging, in the blood. The FDA has actually approved TNF-α reduction as the primary endpoint for our Phase 2 research study, which our company believe positions us well for a successful Stage 2 end result,” said Chris Chapman, M.D., Head Of State, Supervisor as well as Principal Medical Police Officer of MyMD. “The initiation of patient registration in this research study breakthroughs our goal to reduce the aging process, prevent loss of muscle tissue in aging, restriction frailty, and expand healthy life expectancy.”

MyMD has mentioned that there are no FDA-approved medicines for dealing with aging conditions and also prolonging healthy and balanced life-span people, a market expected to be a minimum of $600 billion by 20251 according to a major financial investment bank. TNF-α blockers are one of the most proposed drugs by income, a global market of roughly $40 billion per year,2 and, according to Nature Aging journal,3 a stagnation in aging that would certainly increase life span by one year is worth $38 trillion and by 10 years deserves $367 trillion.

Along with aging, MYMD-1’s unique activity in managing the body immune system as well as dealing with persistent inflammation is being established for the therapy of autoimmune disease, consisting of rheumatoid arthritis (RA), several sclerosis (MS), diabetic issues, as well as inflammatory bowel disease.

” We intend to begin creating protocols for a Stage 2 pilot research of MYMD-1 for rheumatoid arthritis early this year,” Dr. Chapman kept in mind. “The increasing frequency of rheumatoid arthritis and also other autoimmune as well as inflammatory diseases are driving need for TNF inhibitors like MYMD-1, and also our company believe our orally administered medicine with extremely reduced poisoning would certainly be turbulent to the $60 billion market for RA if approved by the FDA for this indication.”

Rheumatoid joint inflammation affects about 40 million people around the world.4.

Regarding MYMD-1.

Originally created for autoimmune diseases, MYMD-1’s key purpose is to slow the aging process, prevent sarcopenia as well as frailty, and also prolong healthy life expectancy. Due to the fact that it can cross the blood-brain barrier and gain access to the central nerve system (CNS), MYMD-1 is additionally positioned to be a possible therapy for brain-related conditions. Its system of action and also effectiveness in illness including several sclerosis (MS) as well as thyroiditis have actually been examined with partnerships with numerous academic organizations. MYMD-1 is also revealing assurance in pre-clinical studies as a prospective therapy for article- COVID-19 complications and as an anti-fibrotic and anti-proliferation restorative.

MYMD-1 has actually shown performance in pre-clinical researches in controling the immune system by performing as a selective inhibitor of tumor death factor-alpha (TNF-α), a vehicle driver of chronic inflammation. Unlike other therapies, MYMD-1 has been displayed in these pre-clinical researches to precisely obstruct TNF-α when it becomes overactivated in autoimmune diseases as well as cytokine tornados, yet not obstruct it from doing its typical task of being a first responder to any routine type of modest infection. MYMD-1’s convenience of oral application is another differentiator contrasted to currently available TNF-α blockers, all of which call for distribution by injection or infusion. No authorized TNF inhibitor has actually ever before been dosed by mouth. Furthermore, the medication is not immunosuppressive and also has not been revealed to create the serious adverse effects usual with conventional therapies that treat swelling.

Regarding MyMD Pharmaceuticals, Inc

. MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a medical phase pharmaceutical business committed to expanding healthy and balanced lifespan, is concentrated on creating 2 unique restorative systems that deal with the causes of disease rather than only dealing with the symptoms. MYMD-1 is a medicine system based on a medical phase small particle that regulates the immune system to control TNF-α, which drives chronic swelling, as well as other pro-inflammatory cell signaling cytokines. MYMD-1 is being created to postpone aging, boost durability, as well as deal with autoimmune diseases and COVID-19- associated depression. The Business’s second medication platform, Supera-CBD, is being established to deal with chronic pain, addiction and also epilepsy. Supera-CBD is a novel artificial by-product of cannabidiol (CBD) and is being developed to resolve as well as surpass the swiftly expanding CBD market, that includes both FDA accepted drugs as well as CBD items not currently controlled as drugs. To learn more, see www.mymd.com.